Clinical Trial Update: Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating HRS-8080 in combination with dalpiciclib isethionate tablets for unresectable or metastatic breast cancer, and the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalpiciclib Isethionate Tablets (dalpiciclib isethionate)
• HRS-8080

Snippet

Sponsor: Shandong Suncadia Medicine Co., Ltd. | Conditions: Unresectable or Metastatic Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING